← Back

Tianjin Zhongxin Pharmaceutical Group Corp Ltd

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited researches, develops, processes, manufactures, and sells traditional Chinese medicine in China. Its products address cardiovascular and cerebrovascular conditions, skin wound repair, health preservation, respiratory, digestive, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, and tumor diseases, as well as chronic conditions and other illnesses, along with tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Founded in 1915, it is based in Tianjin, the People's Republic of China.

Country
Price · split & dividend adjusted
News & notes moving 600329.CG
600329.CG

Darentang's 2026 interim net profit was 645 million yuan, down 66.55% year-on-year

Darentang released its 2026 interim report, with net profit attributable to the parent company of 645 million yuan, a decrease of 66.55% compared with the same period last year. The company's total operating revenue was 2.455 billion yuan, down 7.39% year-on-year; net cash inflow from operating activities was 832 million yuan, up 70.60% year-on-year. The company's latest asset-liability ratio was 43.61%, an increase of 15.69 percentage points from the previous quarter; gross margin was 76.02%, achieving four consecutive years of growth. Diluted earnings per share were 0.84 yuan, down 66.40% year-on-year.
Jiemian·34dRead more →
600329.CG

Darentang Receives Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (I)

The Xinxin Pharmaceutical Factory, a branch of Darentang under Tianjin Pharmaceutical Darentang Group Corporation, has recently obtained the drug registration certificate for Saxagliptin and Metformin Hydrochloride Extended-Release Tablets (I) approved and issued by the National Medical Products Administration. The product specification is each tablet containing saxagliptin 5 mg and metformin hydrochloride 1,000 mg, registered as a Category 4 chemical drug, and deemed to have passed the consistency evaluation. This drug, used in combination with diet and exercise, is indicated for adult patients with type 2 diabetes and was co-developed by Bristol-Myers Squibb and AstraZeneca.
Jiemian·44dRead more →